Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Intra-Cellular Therapies Presents New Efficacy and Safety Data for CAPLYTA in Major Depressive Disorder at ACNP Annual Meeting

Intra-Cellular Therapies presents new data on CAPLYTA's efficacy and safety in treating major depressive disorder at ACNP conference.Quiver AI SummaryIntra-Cellular Therapies, Inc. presented new data on...

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

ITCI : 85.86 (+0.73%)
Insider Sale: Chairman and CEO of $ITCI (ITCI) Sells 1,534 Shares

Sharon Mates, the Chairman and CEO of $ITCI ($ITCI), sold 1,534 shares of the company on 12-05-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.1% of their...

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies Submits Supplemental New Drug Application for CAPLYTA as Adjunctive Therapy in Major Depressive Disorder

Intra-Cellular Therapies submitted an sNDA for CAPLYTA to treat Major Depressive Disorder, demonstrating efficacy and safety.Quiver AI SummaryIntra-Cellular Therapies, Inc. announced the submission of...

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

ITCI : 85.86 (+0.73%)
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

ITCI : 85.86 (+0.73%)

Barchart Exclusives

Xpeng Motors Stock Price Prediction 2025: Is XPEV a Buy or Sell?
Despite having rallied from its 2024 lows, Xpeng Motors shares are in the red in 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar